H.R. 1499: Protecting Consumer Access to Generic Drugs Act of 2019

116th Congress · introduced 2019-03-05 · Health · Latest: Placed on the Union Calendar, Calendar No. 30.

federal

Follow this bill, step by step

Where it came from: introduced 2019-03-05 · official record
Who proposed it: Rep. Rush, Bobby L. [D-IL-1] · what a sponsor is
What happened next: no floor votes in our records yet. Why?
Where it stands now: Placed on the Union Calendar, Calendar No. 30. Not final yet: this can still change. We check for updates every day.
If it becomes law and spends money: follow the money to money laws, then agencies and contracts and grants.

What does this mean?

Official title

Protecting Consumer Access to Generic Drugs Act of 2019

Plain summary

Protecting Consumer Access to Generic Drugs Act of 20 19 This bill prohibits the manufacturer of a brand-name, generic, or biosimilar drug from entering into certain agreements to resolve or settle a patent infringement claim in connection with the sale of a drug or biological product. Specifically, such an agreement shall, with some exceptions, be a violation of the bill if the filer of a subsequent application to market a drug or biological product receives anything of value and agrees to limit or forego research, development, manufacturing, marketing, or sales of the subsequent drug or biological product. (Typically, a subsequent application seeks to market a generic or biosimilar version of a patented drug or biological product.) Penalties for violations of the bill include civil penalties and loss of the 180-day exclusivity period for a generic drug. The Federal Trade Commission (FTC) shall have exclusive authority to litigate to enforce the bill. When a generic or biosimilar drug manufacturer enters into an agreement with another drug manufacturer related to the manufacturing, marketing or sale of a drug, the manufacturers must certify that the material they have given the FTC concerning the agreement contains (1) the complete agreement; and (2) any agreements related to the main agreement, including descriptions of any oral agreements or representations.

Congressional Research Service summary (Reported to House, Part I), quoted unchanged (nonpartisan). Read the source.

What a vote does

A “Yea” vote

If it passes both chambers and is signed, it becomes law.

A “Nay” vote

If it is not passed, current law stays as it is.

PSI Sci description of the legislative step (not an opinion).

What does this mean? (plain words)

Official text

Protecting Consumer Access to Generic Drugs Act of 2019

Source: Congressional Research Service summary (Reported to House, Part I)

AI explanation – may be wrong, check the official text

No AI explanation yet. It takes up to a minute to write and is then saved for everyone.

Limited to a few requests an hour per person.

The strongest published arguments

Arguments for (supporters)

Needs sources: no published arguments on this side yet. We only show items backed by a published source. Suggest one.

Arguments against (opponents)

Needs sources: no published arguments on this side yet. We only show items backed by a published source. Suggest one.

Alternatives

Needs sources: no published alternatives yet (for example a different bill, a law instead of an amendment, or keeping current law). We only show items backed by a published source. Suggest one.

How did my representative vote? · This bill's floor votes

Officials and money

Sponsor: Rep. Rush, Bobby L. [D-IL-1] · 38 cosponsors

Cost estimate: CBO cost estimate: H.R. 1499, Protecting Consumer Access to Generic Drugs Act of 2019 (2019-04-30)

Cosponsors on this site

Frank Pallone, Jr. (D-NJ), Raul Ruiz (D-CA), Debbie Dingell (D-MI), Angie Craig (D-MN), Doris O. Matsui (D-CA), Jefferson Van Drew (R-NJ), Yvette D. Clarke (D-NY), Ro Khanna (D-CA), Janice D. Schakowsky (D-IL), Chris Pappas (D-NH), Steve Cohen (D-TN), Peter Welch (D-VT), John B. Larson (D-CT), Joe Neguse (D-CO), Ed Case (D-HI), Mike Quigley (D-IL), Jamie Raskin (D-MD), Bennie G. Thompson (D-MS), Haley M. Stevens (D-MI), Gilbert Ray Cisneros, Jr. (D-CA), Robin L. Kelly (D-IL), Sean Casten (D-IL), Chrissy Houlahan (D-PA), André Carson (D-IN), Salud O. Carbajal (D-CA), Sharice Davids (D-KS), Adam Smith (D-WA), Lauren Underwood (D-IL)

No linked floor roll calls in our collected records yet. This does not mean the bill has never had a vote. Check the official bill history.

Words on this page, explained (1)

Bill: A proposed law. It becomes law only if it passes the legislature and is signed by the president or governor (or a veto is overridden).

Plain meanings written from linked sources. All words.

Sources

Congressional Research Service summary (Reported to House, Part I)
Congress.gov
Data: GovInfo BILLSTATUS bulk data (Library of Congress), BILLSTATUS-116hr1499.xml <https://www.govinfo.gov/bulkdata/BILLSTATUS/116/hr>

Record fed-us-cong116-hr1499 · catalog fed-us-congress-bills-cong116 · updated 2026-11-15 by psicol fed-bills-cong116